Anti-platelet aggregation of Panax notoginseng triol saponins by regulating GP1BA for ischemic stroke therapy

Abstract Background Panax notoginseng triol saponins (PTS) has been used clinically for ischemic stroke therapy (IST) in China more than 17 years due to its anti-platelet aggregation and neuro-protective effects, but mechanism of action is not fully understand. In this study, aggregation-related protein analysis computer simulations drug-protein binding interactions were performed explore the effects PTS against an ischemia reperfusion model. Methods Three oral doses administered a model middle cerebral artery occlusion (MCAO) rats. total (PNS) combination aspirin chosen comparison. To evaluate therapeutic possible mechanisms aggregation, we measured infarct size water content brain tissue, histomorphological changes, expression related factors (such as arachidonic acid metabolites) platelet receptors serum, well affinity adhesion receptors. Results Compared with PNS, showed stronger potent effect MCAO The could reduce adverse gastrointestinal by regulating TXA 2 /PGI ratio. We demonstrated first time that was able regulate Glycoprotein Ib-? (GP1BA) animal. ginsenoside Rg 1 GP1BA form stable structure. Moreover, von Willebrand factor (VWF)-mediated damaged vascular endothelium, thus enhance probability anti-thrombosis under pathological conditions. Conclusions Our results closely PTS, which provided new scientific molecular evidence clinical application.